Apart from the previously noted findings, there was a marked reduction in Collagen-I levels in skeletal muscle after MSTN-ASO treatment, suggesting an alleviation of muscle fibrosis—a secondary but critical aspect of CKD-induced sarcopenia. This evidence concerns the gene MSTN and chronic kidney disease.